NCT02361060

Brief Summary

Pulmonary complications are relatively frequent after surgery, and can be associated with an increase in morbidity and mortality. Although there are several causative mechanisms that can lead to postoperative pulmonary complications, alterations in the shape and motion of the chest wall are of primary importance. In the investigator´s institution the incidence of postoperatory hypoxemia defined as pO2/FiO2 \<300 is over 20% for patients after major abdominal surgery. Observational and randomized clinical trials have demonstrated that incomplete neuromuscular recovery during the early postoperative period may result in acute respiratory events (hypoxemia and airway obstruction) and an increased risk of postoperative pulmonary complications. A recent study in laparoscopic bariatric surgery showed that patients in which neuromuscular block reversal was done with sugammadex had less chest X-ray pathological changes than those from an historical cohort reversed with neostigmine. The hypothesis is that differences in pulmonary complications, as atelectasis and hypoxemia, between patients reverted with sugammadex or neostigmine may be more apparent with more sensitive techniques like spirometry or lung ultrasound when they exist. Lung ultrasound (LUS) has demonstrated a sensitivity of 90% and a specificity of 98%, to detect alveolar consolidation in critical ill patients while chest radiography data are known to be imprecise.The investigator would like to explore the utility of LUS in postsurgical patients and the relationship between degree of hypoxemia and consolidation area. Objectives:

  • Atelectasis size determined by lung ultrasound (Plannimetry)
  • pO2/FiO2 \<300 1 hour after surgery
  • Explore the accuracy of lung ultrasound (LUS) to diagnosis postoperative atelectasis and its correlation with chest Xray, FVC and pO2/FiO2. Hypotheses:
  • Sugammadex NMB reversal results in a lower reduction of forced vital capacity (FVC) as compared to NMB reversal with neostigmine.
  • Atelectasis is common after major surgery. Size of atelectasis determined by lung ultrasound planimetry is lower one hour after sugammadex reversal as compared to the neostigmine group.
  • The incidence of post-surgical hypoxemia is lower in the sugammadex group as compared to the neostigmine group (Hypoxemia defined as pO2/FiO2 less than 300 is expected in 20% of patients after major abdominal surgery).
  • Lung ultrasound has a better capacity to detect alveolar consolidation than Chest Xray after major surgery.
  • Atelectasis size determine by planimetry has a good correlation with pO2/FiO2 and decrease of FVC after surgery

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
130

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Feb 2015

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 23, 2014

Completed
1 month until next milestone

Study Start

First participant enrolled

February 1, 2015

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 11, 2015

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 4, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 4, 2016

Completed
Last Updated

February 23, 2017

Status Verified

February 1, 2017

Enrollment Period

1.4 years

First QC Date

December 23, 2014

Last Update Submit

February 21, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in FVC at 1h after surgery

    Basal and one hour after surgery

Secondary Outcomes (7)

  • Atelectasis size determined by lung ultrasound (Plannimetry)

    One hour after surgery

  • Atelectasis size determined by lung ultrasound (Plannimetry)

    24 hours after surgery

  • pO2/FiO2 <300

    1 hour after surgery

  • Asociation between atelectasis size and FVC

    1 hour after surgery

  • Asociation between atelectasis size and FVC

    24 hour after surgery

  • +2 more secondary outcomes

Study Arms (2)

Sugammadex

EXPERIMENTAL

sugammadex 4 mg/kg

Drug: Sugammadex

Neostigmine + Atropine

ACTIVE COMPARATOR

Neostigmine 40µg/kg in combination with atropine 10µg/kg.

Drug: NeostigmineDrug: Atropine

Interventions

40mcg/kg

Neostigmine + Atropine

4mg/kg

Sugammadex

10 mcg/kg

Neostigmine + Atropine

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Every patient scheduled for major abdominal surgery (liver resection, pancreatectomy, gastrectomy or any type of colectomy) will be nominated to participate in the study.
  • Informed consent will be asked for after their admission to the hospital the day before the surgery.
  • Patients with postoperative epidural analgesia.

You may not qualify if:

  • Refusal to participate.
  • Entry to postoperative recovery unit under mechanical ventilation.
  • Hypersensitivity reactions to any of the drugs.
  • Severe asthma and mild asthma under treatment.
  • Myocardial infarction or coronary occlusion three months prior to surgery.
  • Myasthenia gravis.
  • Emergency surgery.
  • Pulmonary fibrosis or very severe chronic obstructive lung disease (GOLD IV)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Anesthesiology Service. Hospital Universitario La Princesa

Madrid, Madrid, 28006, Spain

Location

Hospital Universitario de La Princesa

Madrid, Madrid, 28006, Spain

Location

Related Publications (12)

  • Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, Giunta FG, Meistelman C, Prins ME. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008 May;100(5):622-30. doi: 10.1093/bja/aen037. Epub 2008 Apr 2.

    PMID: 18385265BACKGROUND
  • Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008 Nov;109(5):816-24. doi: 10.1097/ALN.0b013e31818a3fee.

    PMID: 18946293BACKGROUND
  • Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009 May;110(5):1020-5. doi: 10.1097/ALN.0b013e31819dabb0.

    PMID: 19387176BACKGROUND
  • Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth. 2008 Oct;101(4):492-7. doi: 10.1093/bja/aen216. Epub 2008 Jul 23.

    PMID: 18653492BACKGROUND
  • Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009 Oct;26(10):874-84. doi: 10.1097/EJA.0b013e32832c605b.

    PMID: 19455040BACKGROUND
  • Yang LP, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs. 2009;69(7):919-42. doi: 10.2165/00003495-200969070-00008.

    PMID: 19441874BACKGROUND
  • Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007362. doi: 10.1002/14651858.CD007362.pub2.

    PMID: 19821409BACKGROUND
  • Ferreyra G, Long Y, Ranieri VM. Respiratory complications after major surgery. Curr Opin Crit Care. 2009 Aug;15(4):342-8. doi: 10.1097/MCC.0b013e32832e0669.

    PMID: 19542885BACKGROUND
  • Squadrone V, Coha M, Cerutti E, Schellino MM, Biolino P, Occella P, Belloni G, Vilianis G, Fiore G, Cavallo F, Ranieri VM; Piedmont Intensive Care Units Network (PICUN). Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. JAMA. 2005 Feb 2;293(5):589-95. doi: 10.1001/jama.293.5.589.

    PMID: 15687314BACKGROUND
  • Yu CJ, Yang PC, Wu HD, Chang DB, Kuo SH, Luh KT. Ultrasound study in unilateral hemithorax opacification. Image comparison with computed tomography. Am Rev Respir Dis. 1993 Feb;147(2):430-4. doi: 10.1164/ajrccm/147.2.430.

    PMID: 8430970BACKGROUND
  • Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010 Jul;111(1):120-8. doi: 10.1213/ANE.0b013e3181da832d. Epub 2010 May 4.

    PMID: 20442260BACKGROUND
  • Tusman G, Bohm SH, Warner DO, Sprung J. Atelectasis and perioperative pulmonary complications in high-risk patients. Curr Opin Anaesthesiol. 2012 Feb;25(1):1-10. doi: 10.1097/ACO.0b013e32834dd1eb.

    PMID: 22113182BACKGROUND

Related Links

MeSH Terms

Interventions

NeostigmineSugammadexAtropine

Intervention Hierarchy (Ancestors)

Phenylammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsOnium Compoundsgamma-CyclodextrinsCyclodextrinsMacrocyclic CompoundsPolycyclic CompoundsDextrinsStarchGlucansPolysaccharidesCarbohydratesAtropine DerivativesTropanesAzabicyclo CompoundsAza CompoundsBelladonna AlkaloidsSolanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsBridged Bicyclo Compounds, HeterocyclicHeterocyclic Compounds, Bridged-Ring

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal investigator.

Study Record Dates

First Submitted

December 23, 2014

First Posted

February 11, 2015

Study Start

February 1, 2015

Primary Completion

July 4, 2016

Study Completion

July 4, 2016

Last Updated

February 23, 2017

Record last verified: 2017-02

Locations